Untoward effects associated with practolol administration: oculomucocutaneous syndrome.
Keratoconjunctivitis sicca, conjunctival scarring, fibrosis, metaplasia, and shrinkage developed in 27 patients as an adverse reaction to practolol. Rashes, nasal and mucosal ulceration, fibrous or plastic peritonitis, pleurisy, cochlear damage, and secretory otitis media also occurred in some cases. Three patients suffered profound visual loss though most retained good vision. Symptoms and signs improved on withdrawal of the drug, but reduction of tear secretion persisted in most patients.
D000328:Adult; D000368:Aged; D001766:Blindness / Q000139:chemically induced; D003051:Cochlea; D003228:Conjunctiva / Q000187:drug effects; D004427:Ear Diseases / Q000139:chemically induced; D005128:Eye Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D007637:Keratoconjunctivitis / Q000139:chemically induced*; D007765:Lacrimal Apparatus / Q000187:drug effects; D008297:Male; D008679:Metaplasia / Q000139:chemically induced; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced; D009668:Nose Diseases / Q000139:chemically induced; D010033:Otitis Media / Q000139:chemically induced; D010538:Peritonitis / Q000139:chemically induced; D010859:Pigmentation Disorders / Q000139:chemically induced*; D010998:Pleurisy / Q000139:chemically induced; D011217:Practolol / Q000009:adverse effects* / Q000494:pharmacology; D013577:Syndrome; D014605:Uveitis / Q000139:chemically induced*; D014607:Uveomeningoencephalitic Syndrome / Q000139:chemically induced
D011217:Practolol